Recently Added |View All
Podcast
What NCI designation means for cancer care in Orange County
In this episode of Physician Huddle by UCI Health, Lindsay Carrillo, MBA, and Sunil Verma, MD, are joined by Richard Van Etten, MD, PhD, director of the Chao Family Comprehensive Cancer Center and holder of the Chao Family Endowed Director’s ...
Video
Where do noncovalent BTK inhibitors fit in chronic lymphocytic leukemia (CLL) care?
Video
Refining Conditioning Intensity for Older Adults Undergoing Transplant
New data presented at ASH 2025 highlight how age, physiologic reserve and toxicity risk should guide conditioning intensity in older patients undergoing transplant.
Video
Rethinking the Biology of Chronic Myeloid Leukemia
New research from UC Irvine challenges a long-standing assumption in chronic myeloid leukemia
News
UCI Health Chao Family Comprehensive Cancer Center among the nation’s best
UCI Health’s Chao Family Comprehensive Cancer Center has been named one of the nation’s top cancer programs.
News
One woman’s fight against rare appendix cancer
After a shocking stage IV cancer diagnosis, patient found hope at UCI Health and turned her recovery into a mission to help others.
News
UCI Health oncologist presents at 2025 ESMO Targeted Anticancer Therapies Asia Congress
Jennifer Valerin, MD, PhD shares early Phase 1 results on BA 3182, a novel bispecific T cell engager, at ESMO TAT Asia 2025.
News
Renowned integrative oncology expert joins UCI Health
Gary Deng, MD, PhD joins to lead a new program blending evidence-based therapies with conventional treatment for whole-person healing.
News
UCI Health faculty share insights and innovations at ASCO 2025
From groundbreaking cervical cancer research to rising investigator talent, UCI Health made a powerful impact at oncology’s biggest stage.
News
UC Irvine clinical research teams advance science for the common good
As the only academic institute in Orange County, UC Irvine prioritizes advancements in science through clinical research.
News
Oncologist's research highlighted at European Lung Cancer Congress 2025
Misako Nagasaka, MD, PhD shares findings showing taletrectinib outperforms crizotinib in ROS1-positive NSCLC.
